Aaron Weaver

Aaron Weaver is a Managing Director at Apeiron Investments focusing on the life sciences sector. He also serves as Senior General Counsel and supports fundraising and investor relations activities at ATAI Life Sciences AG, a clinical-stage biopharmaceutical company specializing in the development of therapeutics for the treatment of mood disorders, addiction and anxiety. He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. He previously worked as an investment banker at Credit Suisse in London within the Capital Markets Solutions team. During his time at Credit Suisse, he advised on capital structuring and issuances for a full spectrum of corporate issuers ranging from pre-revenue companies to publicly listed companies.